Skip to main content
. 2021 Aug 9;1(1):15–37. doi: 10.1021/acsnanoscienceau.1c00009

Figure 26.

Figure 26

Construction of SARS-CoV-2 S1-NanoBiT split luciferase assay. Left: Schematic representation of SARS-CoV-2 viral entry via viral spike protein and cellular ACE2 interaction. Right: Outline of the NanoBiT split luciferase assay for Spike S1 and ACE2 binding upon addition of substrate furimazine. Adapted with permission from ref (124). Copyright 2021 Elsevier B.V.